Table 1. Distribution of latent class membership and care outcomes by race (N = 2,998).
| Overall | non-black | Black | Contrast | |
|---|---|---|---|---|
| N = 2,998 | N = 1,503 | N = 1,495 | ||
| N (%) | N (%) | N (%) | RFD (95% CI)* | |
| Latent class domains | ||||
| Socioeconomic status (SES) | ||||
| High SES | 1,100 (37%) | 757 (50%) | 343 (23%) | ref |
| Moderate SES | 726 (24%) | 257 (17%) | 469 (31%) | 14.3 (11.2, 17.3) |
| Low SES | 1,172 (39%) | 489 (33%) | 683 (46%) | 13.2 (9.7, 16.6) |
| Care barriers | ||||
| Fewer barriers | 2,478 (83%) | 1,346 (90%) | 1,132 (76%) | ref |
| More barriers | 520 (17%) | 157 (10%) | 363 (24%) | 13.8 (11.2, 16.5) |
| Care use | ||||
| Short travel, high use | 1,750 (58%) | 868 (58%) | 882 (59%) | ref |
| Short travel, low use | 415 (14%) | 136 (9.0%) | 279 (19%) | 9.6 (7.2, 12.1) |
| Medium travel | 551 (18%) | 336 (22%) | 215 (14%) | −8.0 (−10.7, −5.2) |
| Variable travel | 164 (5.5%) | 100 (6.7%) | 64 (4.3%) | −2.4 (−4.0, −0.7) |
| Long travel | 118 (3.9%) | 63 (4.2%) | 55 (3.7%) | −0.5 (−1.9, 0.9) |
| Care outcomes | ||||
| Diagnosis | ||||
| Not delayed | 2,450 (82%) | 1,280 (85%) | 1,170 (78%) | ref |
| Delayed | 545 (18%) | 222 (15%) | 323 (22%) | 6.9 (4.1, 9.6) |
| Treatment initiation | ||||
| Not delayed | 1,942 (65%) | 1,033 (69%) | 909 (61%) | ref |
| Delayed | 1,053 (35%) | 469 (31%) | 584 (39%) | 7.9 (4.5, 11.3) |
| Treatment duration | ||||
| Not prolonged | 1,326 (52%) | 681 (54%) | 645 (50%) | ref |
| Prolonged | 1,242 (48%) | 584 (46%) | 658 (50%) | 4.3 (0.5, 8.2) |
| Receipt of OncotypeDx | ||||
| Tested | 609 (38%) | 401 (43%) | 208 (31%) | ref |
| Not tested | 1,006 (62%) | 537 (57%) | 469 (69%) | 12.2 (7.3–16.7) |
* Relative frequency difference (RFD, expressed as a percentage difference on the absolute scale) and 95% confidence interval, comparing frequencies of latent class domains between black women and non-black women (referent group).
Latent variables were defined for SES (income, education, country of birth, job type, and marital status), care barriers (insurance, urban/rural status, job loss, self-reported financial barriers to care, self-reported transportation barriers to care), and care use (pre-diagnostic regular care, breast cancer screening, mode of initial cancer detection (mammogram vs. noticed lump), and travel (based on estimated driving time) to diagnosis and surgery).
OncotypeDx is a genomic test of breast cancer tissue used to assess risk of recurrence and inform chemotherapy treatment decisions.